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ABSTRACT
Purpose To determine drug precipitation during in vitro lipolysis
of a lipid-based drug delivery system (LBDDS) using Raman
spectroscopy as a real-time monitoring technique. A second
aim was to describe the kinetics of lipolysis-triggered drug
precipitation using a theoretical nucleation and growth model.
Methods A model LBDDS containing different concentration
of fenofibrate was digested in vitro and drug precipitation was
determined after ultracentrifugation and nanofiltration (off-line
methods), as well as by Raman spectroscopy (in-line method).
Subsequently, a theoretical nucleation and growth model was
fitted to the obtained drug crystallization profiles by considering
the lipolysis-triggered change in drug solubility.
Results Compared with standard off-line measurements,
Raman spectroscopy enabled a more robust and highly time-
resolved analysis of lipolysis-triggered drug precipitation.
Although the formulation was rapidly digested, fenofibrate
remained in a supersaturated state for several minutes before
beginning to crystallize. The in vitro digestion results were in
excellent agreement with the theoretical model (R2>0.976).
Conclusions The combination of real-time Raman spectroscopy
and mathematical modeling provided insights into the kinetics of
lipolysis-triggered drug crystallization. This knowledge allows a
better biopharmaceutical understanding and will, ultimately, lead
to the improved development of lipid-based drug formulations.
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ABBREVIATIONS
4-BPBA 4-bromophenylboronic acid
DG Diglycerides
DLS Dynamic light scattering
FA Fatty acids
HPLC High-performance liquid chromatography
LBDDS Lipid-based drug delivery systems
MG Monoglycerides
MSC Multiple scattering correction
NaTDC Sodium taurodeoxycholate
PC Phosphatidylcholine
PDI Polydispersity index
PLS Partial least squares
RMSEC Root-mean-square error of calibration
RMSECV Root-mean-square error of cross-validation
SG Savitzky-Golay
S(M)EDDS Self-(micro)emulsifying drug delivery system
SNV Standard normal variate
TG Triglycerides
XRPD X-ray powder diffraction
INTRODUCTION
Contemporary drug discovery screening has generated an in-
creasing number of highly active but poorly water-soluble drug
candidates. Lipid-based drug delivery systems (LBDDS) are an
innovative strategy that significantly enhances the oral bioavail-
ability of such compounds. Because the formulated drug is
already in a dissolved state, the critical dissolution step is
circumvented. This is, however, only one mechanism by which
LBDDS can enhance oral drug absorption. Drug solubilization
in the intestinal medium is generally improved in the presence
of lipidic excipients. Furthermore, these excipients can stabilize
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a supersaturated drug, may reduce pre-systemic clearance, and
can promote lymphatic absorption (1–4).
The improvement of oral bioavailability is largely
governed by the fate of the LBDDS in the gut. In
addition to formulation dispersion, digestion represents
a particularly critical step, because hydrolyzed glycerides
and some surfactants exhibit a change in polarity (5–7).
Thus, the capacity of a formulation to solubilize a drug
may be progressively reduced, developing an increased
risk of drug precipitation. To predict the fate of a drug
in the gastrointestinal lumen therefore requires adequate
in vitro tests. Although no standard compendial methods
have been established so far, first attempts have been made in
this direction (7–10). Most recently, the Lipid Formulation
Classification System Consortium released a collaborative
work, which was aimed at standardizing in vitro methods to
assess the performance of LBDDS, with a particular focus on
lipolysis testing (11,12).
A lipolysis test should primarily reveal whether a
formulation keeps the drug solubilized. According to
the current procedure, samples are removed at given
time intervals during a digestion experiment (11,13).
After enzyme inhibition, the digests are separated by
ultracentrifugation into a pellet phase (containing precipitated
drug), an oil phase, and an aqueous phase. The drug distri-
bution in these phases is crucial, because the solubilized drug
is expected to approximate the dose fraction that is available
for absorption (14).
The influence of lipid digestion on drug solubilization is
the result of a complex interplay between several factors.
Relevant for solubilization are the properties of the drug
and of the lipolysis products in the presence of bile salts and
phospholipids. It is assumed that colloidal structures, which
are generated during formulation lipolysis, largely define
drug solubilization. Although these structures have been
characterized in several studies (15–21), it is difficult to
predict the resulting drug solubilization. The difficulty arises
not only from dynamic changes in the medium but also from
the possibility of drug supersaturation. Indeed, if the period
of supersaturation is long enough to enable drug absorption,
then intestinal drug precipitation might be prevented. Thus,
considerable research efforts have focused on drug super-
saturation in biorelevant media, with and without the aid of
lipid-based excipients (4,22,23). As well as drug supersatu-
ration, the solid-state properties of precipitated drug are of
biopharmaceutical relevance. Sassene et al. recently ob-
served the precipitation of amorphous cinnarizine dur-
ing digestion of a self-emulsifying system (24). Drug re-
dissolution was measured in vitro and proved to be faster
than from its crystalline form. Such knowledge appears
to be critical to the development of a formulation and
indicates that more research is needed in this pharma-
ceutical field.
Formulation digestion and drug solubilization are highly
dynamic processes, but the lack of real-time information
limits the feasibility of exploring in vitro digestion. Warren
et al. recently demonstrated the importance of using an in situ
method (synchrotron small-angle X-ray scattering) to gain
insight into a rapidly proceeding digestion process (25).
Significant transformations of the formulation typically oc-
cur within a short time frame and the sampling regime of
traditional methods almost precludes the detection of tran-
sient solubility effects.
The use of Raman spectroscopy is an efficient approach to
the real-time monitoring of crystallization processes during
chemical production (26–31). The method allows rapid spectra
collection in a contact-free manner and with high chemical
specificity. Recently, Raman spectroscopy has been applied
successfully to study drug precipitation in a biorelevantmedium
(32) and for process monitoring in complex multiphasic systems
(33). These are promising features with respect to real-time
monitoring of drug crystallization during in vitro digestion.
However, the complexity of the medium and the varying
composition during lipolysis are particularly challenging for
any spectroscopic application.
The first aim of the study was to evaluate the potential of
Raman spectroscopy for real-time monitoring of drug pre-
cipitation during in vitro lipolysis. Based on this in situ infor-
mation, the second aim was to describe the kinetics of drug
precipitation using a theoretical model of nucleation and
particle growth, including the lipolysis-triggered change in
drug solubility. Finally, using the combination of real-time
spectroscopy and mathematical modeling, we aimed to gain
a better quantitative understanding of lipolysis-triggered
drug precipitation.
MATERIALS AND METHODS
Materials
We obtained fenofibrate (2-[4-(4-chlorobenzoyl)phenoxy]-
2-methylpropionic acid 1-methylethyl ester, ≥99%),
Trizma® maleate, calcium chloride dihydrate (≥99%), pan-
creatin (from porcine pancreas, 8xUSP specifications), 4-
bromophenylboronic acid (4-BPBA, ≥95.0%), chloroform,
and acetonitrile from Sigma-Aldrich Chemie GmbH
(Buchs, Switzerland), and sodium chloride (≥99%) from
Carl Roth GmbH (Karlsruhe, Germany). Lipoid E PC S
(phosphatidylcholine from egg yolk) was supplied by Lipoid
GmbH (Ludwigshafen, Germany), sodium taurodeoxycho-
late by Prodotti Chimici e Alimentari S.p.A. (Basaluzzo,
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Italy), and sodium hydroxide 1 M by Scharlab S.L.
(Sentmenat, Spain). Imwitor® 988 was purchased from
Sasol Germany GmbH (Witten, Germany), Miglyol 812 N
from Hänse ler AG (Herisau, Switzer land) , and
Cremophor® RH 40 from BASF AG (Ludwigshafen,
Germany). Imwitor® 988 was a blend of medium-chain
mono-, di-, and triglycerides (54.6% monoglyceride [MG],
38.0% diglyceride [DG], and 7.1% triglyceride [TG]) con-
sisting of 98.7% w/w caprylic acid (C8), 1.1% w/w capric
acid (C10), and 0.1% w/w caproic acid (C6), with average
molecular weights of 197, 340, and 483 g/mol for MG, DG,
and TG, respectively (according to the certificate of analysis,
lot no. 003041, Cremer Oleo GmbH). Miglyol 812 N was a
medium-chain TG consisting of 57.9% w/w caprylic acid
(C8), 41.2% w/w capric acid (C10), 0.5% w/w lauric acid
(C12), and 0.1% w/w caproic acid (C6) with an average
molecular weight of 517 g/mol (according to the certificate
of analysis, lot no. 2008111435, Hänseler AG).
Purified water was prepared with an Arium® 61215
water-purification system from Sartorius Stedim Biotech
GmbH (Göttingen, Germany). We used Anotop® 25 Plus
filters (aluminum oxide, 0.1 μm) purchased from Whatman
GmbH (Dassel, Germany) for nanofiltration.
Preparation of the Model Formulation
A self-microemulsifying drug delivery system (SMEDDS) was
selected as the model formulation. The SMEDDS was com-
posed of 40%w/wMiglyol 812, 20%w/w Imwitor® 988, and
40%w/wCremophor®RH40. The components were mixed
on a magnetic stirrer at 40°C until a clear solution was
obtained and then slowly cooled to room temperature.
Fenofibrate (logP 4.6) was used as a poorly water-soluble
model drug. The compound was incorporated into the for-
mulation at levels of 20, 30, 40, 50, 60, 70, and 80 mg/g
(Cform). All formulations were visually assessed for absence of
undissolved drug particles.
In Vitro Lipolysis Test
The in vitro lipolysis test was performed as described in the
literature (7). We prepared a micellar solution containing
1.25 mM phosphatidylcholine (PC) and 5 mM sodium taur-
odeoxycholate (NaTDC) to simulate fasted state intestinal
conditions. PC was dissolved in chloroform and the solvent
was evaporated under vacuum (Rotavapor RE 120, Büchi,
Switzerland). NaTDC and digestion buffer (50 mM
Trizma® malea te , 150 mM NaCl , and 5 mM
CaCl2∙2H2O; pH7.5) were then added and the mixture
was stirred for 12 h (450 rpm, 5°C). To prepare the pan-
creatin extract, we mixed 1 g of porcine pancreatin powder
per 5 ml of digestion buffer (5°C), stirred for 15 min, and
then centrifuged the suspension (15 min, 1,600xg, 5°C).
Finally, the supernatant was collected and the pH adjusted
to 7.5, which corresponded to the pH of the lipolysis medi-
um. The pancreatin extract was freshly prepared each day
and stored on ice until use.
The micellar solution (108 ml) was transferred to a
thermostated glass vessel (37.0±0.5°C) and the formula-
tion (2.6 g) was added. The mixture was stirred for
10 min for complete dispersion, thermal equilibration,
and pH adjustment to 7.500±0.001. For mixing, we
used a magnetic stirrer (3 cm in diameter) at a speed
of 450 rpm. Digestion was initiated by the addition of
12 ml pancreatin extract (final nominal lipase activity:
1000 tributyrin units per ml). The free fatty acids (FA)
produced during lipolysis were titrated using 1 M NaOH
to maintain pH7.500 using a pH-stat apparatus (842
Titrando and 800 Dosino, Metrohm AG, Switzerland),
which was operated using the Tiamo 1.2 software pack-
age (Metrohm AG, Switzerland). Lipolysis was allowed to
proceed for 30 min.
To determine the NaOH consumption caused by
digestion of the blank digestion medium, we performed
the lipolysis test with pure digestion medium without
formulation (n=3).
Fenofibrate formulations with varying drug loads (20, 30,
40, 50, 60, 70, and 80mg/g) were digested in triplicate and the
amount of precipitated and/or solubilized drug was assayed
using three different procedures, i.e., ultracentrifugation,
nanofiltration, and Raman spectroscopy.
“Back-Titration” and Calculation of Free Fatty Acids Liberated
During Digestion
It was previously shown that the titrated NaOH volume
represents only an approximation of the free fatty acids
(FA) liberated during lipolysis. Some FA exist in their union-
ized state, according to the pKa value, leading to an under-
estimation of the total FA liberation. This must be corrected
by a procedure that was previously termed “back-titration”
(34,35). We performed the back-titration experiment as
described in the literature, with minor changes. At the end
of the 30 min digestion period, the pH was rapidly increased
to 9 by addition of 1 M NaOH for complete FA
ionization (deprotonation). The experiment was also
done with blank digestion buffer including pancreatin
extract (without formulation, PC, and NaTDC) to de-
termine the NaOH volume needed to increase the pH
in the absence of lipolysis products. The latter volume
was subtracted from the total back-titration volume
obtained in the presence of lipolysis products to obtain
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the value of FAtitr(back-titration). The correction factor
was calculated according to the formula:
Correction factor ¼ FAtitr direct titrationð Þ þ FAtitr back  titrationð Þ
FAtitr direct titrationð Þ
ð1Þ
where FAtitr(direct titration) is the amount of FA titrated
after the 30 min digestion period.
A correction factor was calculated for both the lipol-
ysis of formulations and the lipolysis of pure digestion
medium (without formulation). Finally, the amount of
FA liberated from the pure digestion medium was sub-
tracted from the total amount of FA titrated in presence
of the SMEDDS.
Determination of Drug Precipitation
Ultracentrifugation Method
During formulation lipolysis, aliquots (2.7 ml) were taken
from the digestion media after a 1, 2.5, 5, 7.5, 10, 12.5, 15,
20, 25, and 30 min digestion period. We immediately added
20 μl of a 4-BPBA solution (1 M in methanol) to inhibit
further lipolysis (36) and ultracentrifuged the samples
(80,000×g, 37°C, 90 min) in a Centrikon T-1180 ultracentri-
fuge equipped with a TFT-80.4 fixed-angle rotor (Kontron
Instruments,Milan, Italy). The aqueous phase was then diluted
with acetonitrile and centrifuged (16,000xg, 15min). The pellet
was suspended in purified water, diluted in acetonitrile, and
centrifuged (16,000xg, 15 min). Finally, all samples were
analyzed using high-performance liquid chromatography
(HPLC).
Nanofiltration Method
A 2 ml sample was withdrawn from the lipolysis medium after
1, 2.5, 5, 7.5, 10, 12.5, 15, 20, 25, and 30 min. The samples
were directly passed through an Anotop® 25 Plus syringe
filter (pore size 0.1 μm, aluminum oxide filter membrane)
(37) and the filtrate was immediately diluted in acetonitrile
to stop further lipolysis. The samples were then centrifuged
(16,000xg, 30 min) and analyzed by HPLC. We verified
experimentally that no loss of dissolved substance occurred
through adsorption onto the filter material.
The Mann–Whitney test was performed to compare the
concentration of solubilized drug after 0 and 1 min of lipolysis.
For statistical treatments we used the software Statgraphics®
Centurion XV Professional (Statpoint Technologies Inc.
Warrenton, USA) and selected a significance level of
95.0% (p<0.05).
In-line Determination of Drug Precipitation Using Raman
Spectroscopy
A multi-fiber Raman PhAT probe was used to deter-
mine the course of fenofibrate precipitation in situ. The
titration vessel was covered with a custom-built vessel
lid (Metrohm AG, Zofingen, Switzerland) with an extra
cavity for the PhAT probe, which was positioned 1 cm
above the initial level of the lipolysis medium (Fig. 1). A
comparatively large titration vessel, and thus a relatively
high volume of digestion medium, were required because of
the PhAT probe size (outer diameter: 32 mm). The entire
lipolysis vessel was wrapped in aluminum foil and the labora-
tory was darkened to avoid the influence of external light on
the Raman signal.
We used aRamanRXN1 analyzer (KaiserOptical Systems,
Inc., Ann Arbor, MI, USA) equipped with a charge-coupled
device (CCD) camera and a diode laser operating at a wave-
length of 785 nm.The spectra were acquired with a laser power
of 400 mW and background Rayleigh scattering was re-
moved by a holographic filter during spectra acquisition. A
single spectrum was acquired every 20 s (acquisition time
18.5 s) with a resolution of 4 cm−1 using the iC Raman
Instrument software (Version 3.0, Mettler-Toledo AutoChem
Inc., Columbia, MD, USA). The Raman PhAT probe was a
multi-fiber probe with a non-contact sampling optic device
having a laser spot diameter of 6 mm. The scattered radi-
ation was collected by an array of 50 optical fibers and
delivered to the CCD camera.
To remove sources of non-linearity and spectral informa-
tion that was uncorrelated with the concentration of the
analyte, the spectra were subjected to several pre-
processing algorithms, i.e., the multiplicative scatter correc-
tion (MSC) (38), the standard normal variate (SNV)
Fig. 1 Experimental setup of the in vitro lipolysis test combined with
Raman spectroscopy. The PhAT probe consisted of a non-contact optic
device and provided a large laser spot area (6 mm in diameter).
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transformation (39), and the Savitzky-Golay (SG) polynomi-
al derivative filter (40). All data were mean-centered and,
finally, a calibration model was built by partial least-squares
(PLS) regression (41). The optimal number of PLS factors
was defined where the root-mean-square error of cross-
validation (RMSECV) reached a minimum (<1% of spec-
tral variation). Cross-validation was performed with the
leave-one-out method. We evaluated different spectral
ranges to include in the PLS regression model, i.e., the entire
spectrum (500–1800 cm−1), the fingerprint range of fenofi-
brate (1000–1800 cm−1), and specific fenofibrate peaks
(1132–1164 cm−1, 1550–1615 cm−1, and 1635–
1663 cm−1). Spectral preprocessing and PLS regression
analysis were calculated using MATLAB® (MathWorks,
Naticks, MA, USA). The calibration models were evaluated
in terms of the correlation coefficient R2, the cross-
validation coefficient Q2, the root-mean-square error of
calibration (RMSEC), and the RMSECV.
Drug Solubilization Upon Dispersion
Without Lipolysis
Drug solubilization under non-digesting conditions was
determined to assess whether fenofibrate precipitated
spontaneously upon aqueous dispersion of the formula-
tion (without lipolysis). Thus, 2.6 g of SMEDDS with
80 mg/g fenofibrate were dispersed in 108 ml of diges-
tion buffer (containing NaTDC and PC) in a glass
vessel at 37°C and stirred at 450 rpm. After equilibrat-
ing the system for 10 min, 12 ml of pure digestion
buffer (without pancreatin extract) were added and the medi-
um was stirred for 30 min. Subsequently, three 2 ml aliquots
were centrifuged for 30 min (16,000xg, 37°C) and the con-
centration of solubilized and precipitated fenofibrate was
measured by HPLC. The experiment was carried out in
triplicate.
Determination of Drug Solubility
Drug solubility was determined in the undiluted formulation
(C*form). Excess solid drug was added to a 2 ml aliquot of blank
formulation and stored in hermetically sealed glass vials
during equilibration (37°C, 450 rpm). After 24 h, 48 h,
and 72 h the samples were centrifuged (37°C, 16,000xg,
30 min) and the supernatant was analyzed by HPLC.
Equilibrium was assumed when two consecutive solubility
samples varied by ≤5% (w/w).
Furthermore, we determined the drug solubility (C*m;t ) in
the lipolysis medium containing drug-free SMEDDS after a
1, 2.5, 5, 7.5, 10, 12.5, 15, 20, 25, and 30 min digestion
period. The enzyme inhibitor (4-BPBA, 1 M in methanol,
9 μl per ml of digest) was added to the medium at the
aforementioned time points to stop further digestion.
Excess solid drug was transferred to a 10 ml aliquot of the
lipolysis medium and was hermetically sealed in glass vials.
After equilibration (450 rpm, 37°C), the samples were ultra-
centrifuged (80,000×g, 37°C, 90 min). The liquid phase was
then diluted in acetonitrile, centrifuged (16,000xg, 15 min),
and finally analyzed by HPLC. Because the solubilities were
found to decrease at equilibration times longer than 24 h,
we considered the value obtained at 24 h of equilibration as
the relevant solubility. The observed decrease in solubility
was attributed to kinetic instability of the colloidal struc-
tures in digested medium (4,12). Whenever a lipid phase
was obtained upon ultracentrifugation, the lipid and the
aqueous phase were re-emulsified, to measure the overall
concentration of solubilized drug. The drug solubility experi-
ments were carried out in triplicate.
High-Performance Liquid Chromatography (HPLC)
For HPLC analysis (Agilent Technologies 1200 Series) we used
an isocratic pump (G1310A), an autosampler (G1329A), and a
variable wavelength detector (G1310A). All measurements
were done on a LiChrospher® 60, RP select B 125–4 (5 μm)
column (Merck, Darmstadt, Germany), using a flow rate of
1 ml/min, a UV detection wavelength of 287 nm, and an
injection volume of 20 μl. The mobile phase consisted of
acetonitrile and ammonium acetate buffer (pH3.5; 25 mM)
at a ratio of 65:35 (v/v) (42). All sample measurements were in
the linear range of calibration.
Dynamic Light Scattering (DLS)
We measured the particle size of the dispersed formu-
lation before lipolysis initiation by DLS using a Zeta
Sizer Nano ZS (Malvern Instruments, Malvern, UK),
equipped with a 4 mW He-Ne Laser operating at a
wavelength of 633 nm. The scattering signal was detected at
an angle of 173° and each sample was measured in
triplicate for 10 min. The result was expressed as inten-
sity averaged particle diameter (nm) and as polydispersity
index (PDI).
X-ray Powder Diffraction (XRPD)
The pellet phase that was obtained upon digestion and
ultracentrifugation of the drug-containing formulation was
analyzed by XRPD. The formulation with 80 mg/g fenofi-
brate was digested for 30 min in the in vitro lipolysis test and,
after enzyme inhibition, an aliquot was ultracentrifuged
(80,000× g, 37°C, 90 min). The pellet phase was
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immediately isolated and an X-ray diffractogram was
recorded. The same procedure was followed with the pellet
phase obtained from a 30 min lipolysis experiment with
drug-free formulation, which was spiked with an equal
amount of pure fenofibrate (as used for formulation prepa-
ration). Moreover, we recorded the X-ray diffractogram of
crystalline fenofibrate as a reference.
We used a theta-theta X-ray powder diffractometer
(R-XRD Phaser D2, Bruker AXS GmbH, Karlsruhe,
Germany) equipped with a Co and Cu KFL tube (30 kV,
10 mA) as radiation source and a Lynxeye® detector.
The samples were scanned in the angular range of
5° (2θ) to 40° (2θ) with a step size of 0.1° (2θ) and a
count time of 5 s per step.
Modeling the Kinetics of Lipolysis-Triggered Drug
Precipitation
The increased chemical potential of a supersaturated
solution, in which the actual concentration of solubilized
drug exceeds its solubility, is the driving force for drug
precipitation. Precipitation can be described by two
consecutive processes, i.e., nucleation and particle
growth. The relationship between precipitation and su-
persaturation is reflected in the expressions describing
the kinetics of these processes. According to the classical
nucleation theory, the nucleation rate, J (m−3s−1), is
given by (43):
J ¼ dC
0
pr
dt
¼ A0 S e Bln2S ð2Þ
where C
0
pr is the number of nuclei formed per unit
volume and S is the degree of supersaturation given
by S=C/C*, with C being the actual drug concentration
and C* its solubility in themedium. Parameter A' (m−3s−1) holds
for the kinetic component of nucleation and is proportional to
the number of nucleation-active centers. Its value differs be-
tween volume-diffusion-controlled and interface-controlled nu-
cleation and is many orders of magnitude smaller for
heterogeneous nucleation than for homogeneous nucleation
(44). B stands for the thermodynamic component of the process
and is given by:
B ¼ 16pn20g3=3 kTð Þ3 ð3Þ
where n0 is the molecular volume of the crystalline
phase, γ is the interfacial energy per unit area of the
crystal, k is the Boltzmann constant, and T is the temperature.
In the case of heterogeneous nucleation, the work of nucle-
ation is reduced because of the lower interfacial energy, lead-
ing to smaller values of B.
The particle growth rate G (m·s−1) is often expressed
heuristically as a power-law (45):
G ¼ k 0g C  C*
 g ð4Þ
where k
0
g is the particle growth coefficient, and g is the order
of particle growth.
To apply Eqs. 2 and 4 for modeling the kinetics of
lipolysis-triggered drug precipitation, the changes in C*
and S as a function of time had to be considered.
Fenofibrate solubility depends on the concentration of lipids
in the medium and is therefore affected by the lipolysis,
which changes the lipid composition over time. Hence,
solubility was expressed as a function of time by a heuristic
equation, which considered the contribution of different
lipid species to solubility.
Considering the lipolysis kinetics on the one hand,
and the specificity/activity of digestive enzymes (i.e.,
pancreatic lipase, co-lipase, and carboxyl ester hydro-
lase (7,34,35,46)) on the other, we subdivided the li-
polysis of the formulation (containing TG, DG, and
MG) into two kinetic stages. TG and DG were as-
sumed to be digested rapidly by the pancreatic lipase
and co-lipase (first stage), while MG were digested
slowly by the carboxyl ester hydrolase (second stage).
The time point of transition between the first and
second stages, tx, was obtained graphically from the
experimental FA titration curve. Based on the titration
data and the stoichiometry of glyceride lipolysis, we
calculated the moles of TG and DG (M1(t)) digested
into MG during the first stage and the moles of MG
(M2(t)) digested during the second stage. The course of
drug solubility in both stages was modeled using Eqs. 5
and 6:
C*m;t stage 1ð Þ ¼ C*m;0& 1 
M1ðtÞ
M0
 
þ C*m;tx&
M1ðtÞ
M0
 
ð5Þ
C*m;tðstage 2Þ ¼ C*m;tx  C*m;30
 
& 1 M2ðtÞ
Mtx
 
þ C*m;30 ð6Þ
where C*m;0 , C
*
m;tx , and C
*
m;30 are the experimental drug
solubility values in the lipolysis medium at times 0, tx, and
30 min, respectively. M0 is the molar quantity of TG and
DG at 0 min, and Mtx is the molar quantity of MG in the
medium at tx. M1(t) and M2(t) were proportional to the
logarithm of time.
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The kinetics of lipolysis-triggered drug precipitation
was modeled by adapting Eqs. 2 and 4, and combining
them with Eqs. 5 and 6. Three time intervals were
defined that were delimited by t0 (beginning of the
experiment), tn (beginning of nucleation), tg (beginning
of particle growth), and t30 (end of the experiment).
Thus, the model comprised the following system of
ordinary differential equations:
If t0 < t < tn :
dCpr
dt
¼ 0 ð7Þ
if tn < t < tg and t < tx :
dCpr
dt
¼ A S e Bln2S with S ¼ C
C*m;t stage 1ð Þ
ð8Þ
if tn < t < tg and t > tx :
dCpr
dt
¼ A S e Bln2S with S ¼ C
C*m;t stage 2ð Þ
ð9Þ
if tg < t < t30 and t < tx :
dCpr
dt
¼ kg C  C*
 g
with C* ¼ C*m;t stage 1ð Þ
ð10Þ
if tg < t < t30 and t > tx :
dCpr
dt
¼ kg C  C*
 g
with C* ¼ C*m;t stage 2ð Þ
ð11Þ
Cpr refers to the mass concentration of precipitated
drug. During the induction time (between t0 and tn),
no precipitation takes place (Eq. 7). During nucleation,
the degree of supersaturation S may be given by Eqs. 8
and 9 depending on the position of tx relative to tn and
tg. Analogously, during particle growth, the expression of
solubility C* may depend on the position of tx with
respect to tn and tg (Eqs. 10 and 11).
The values of parameters A, B, kg, g, tn, and tg, were
estimated by regressing this system of differential equations
to the concentration data obtained by Raman spectroscopy.
Mean Cpr values of each drug load between 40 and 80 mg/g
(n=3) were used. Calculations were carried out using
MATLAB. For parameter estimation we used the
MATLAB optimization algorithm fminsearch, which is based
on the simplex procedure. The ordinary differential equa-
tions were numerically solved using the MATLAB ode45
solver and the model quality was assessed based on the R2
value and the root-mean-square error (RMSE).
RESULTS
Formulation Characteristics
The lipid-based system emulsified spontaneously within 10 s,
resulting in a fine emulsion with a droplet diameter of 39.5±
0.3 nm and a PDI of 0.047±0.018 (mean±standard devia-
tion, n=3). No drug precipitation was measured 30 min after
dispersion under non-digesting conditions. Fenofibrate solu-
bility in the undigested lipolysis medium was 2.60±
0.44 mg/ml. However, upon addition of pancreatin extract,
the solubility dropped rapidly to a value of 0.403±
0.006 mg/ml within the first minute of digestion. By the end
of the lipolysis experiment (t=30 min), solubility further
decreased to 0.129±0.005 mg/ml. On the other hand,
fenofibrate solubility in the undispersed formulation,
C*form, was 139.6±0.7 mg/g.
Before lipolysis initiation, fenofibrate was below saturation,
even at the highest drug load. As a consequence of the rapid
decrease in drug solubility with formulation lipolysis, fenofi-
brate became supersaturated within the first minute of diges-
tion. At the highest drug load (80 mg/g) the supersaturation
ratio reached a value of 4.19±0.03 (1 min of digestion),
whereas at a drug load of 20 mg/g, the corresponding super-
saturation ratio was 1.04±0.02.
Figure 2 shows the NaOH titration profile obtained from
formulation lipolysis. Immediately after initiation of digestion, the
hydrolysis was fast, while after approximately 1 min the rate had
clearly decreased. No clear differences were observed between
the lipolysis profiles of formulations with different drug loads.
Because not all FA were expected to be ionized at the pH
of the assay, we employed the “back-titration” procedure.
We obtained a back-titration factor of 1.09 for the formu-
lation lipolysis, implying that 9% of the free FA were pro-
tonated at pH7.5 and, thus, not determined by direct
titration. The lipolysis and back-titration of pure digestion
medium (without SMEDDS) resulted in a correction factor
of 1.77.
Detection of Drug Precipitation During Lipolysis
Ultracentrifugation Method
To determine the amount of precipitated drug, we first
applied ultracentrifugation for sample preparation, which
appeared to be the most widespread method in this field of
in vitro testing. Following ultracentrifugation, only two
phases were obtained, i.e., an aqueous and a pellet phase.
No oil phase was visually detectable with the given samples.
This was, as expected, different from the samples that were
not digested (t=0), in which an oil phase was additionally
observed.
3120 Stillhart, Imanidis and Kuentz
Figure 3a displays the fenofibrate precipitation profiles
of formulations with varying drug loads, as obtained
using ultracentrifugation. Drug precipitation started rap-
idly upon initiation of digestion and leveled off after
approximately 2.5 min for formulations with drug loads
of 40 to 80 mg/g. Formulations with a lower drug load
displayed some drug precipitation as well but the rates
and extents were moderate.
Drug concentration in the aqueous phases decreased
over time, in parallel to the increase in precipitation. After
a 2.5 min digestion period, the concentrations of solubilized
drug approached the equilibrium values, C*m;t; for all for-
mulations with a drug load of 40–80 mg/g.
We recorded the XRPD pattern of pure fenofibrate, of
the pellet containing precipitated fenofibrate, and of a ref-
erence pellet. This reference was the pellet obtained after
lipolysis of drug-free formulation, which was spiked with
crystalline fenofibrate. As seen in Fig. 4, the angular range
of peaks of the pellet containing precipitated drug corre-
sponded to that of the reference pellet. Therefore, appar-
ently, fenofibrate precipitated in the crystalline form during
lipolysis.
Nanofiltration Method
The nanofiltration method allowed the determination of
solubilized fenofibrate in the filtrate. Therefore, the concen-
tration of precipitate was calculated as the difference between
the total drug concentration and the amount of solubilized
drug (Fig. 3b).
Similar to the ultracentrifugation method, we observed
significant drug precipitation within 30 min of lipolysis with
all formulations having a drug load of 40 mg/g and more.
However, the time course was different, as there was an
initial lag phase without precipitation before the drug finally
started to precipitate out. Thus, for the SMEDDS with the
highest drug load, precipitation started after approximately
2.5 min, while for the formulation with a drug load of
30 mg/g, drug precipitated after about 15 min. The
concentration of solubilized drug did not significantly change
within the first minute of digestion for each drug load
(p>0.05). Finally, only minimal precipitation was observed in
the formulation with a 20 mg/g drug load.
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Fig. 3 Time course of fenofibrate precipitation during formulation
lipolysis as detected (a) upon ultracentrifugation, (b) upon nano-
filtration, and (c) with Raman spectroscopy. Each color represents a
single drug loading, Cform. Values are expressed as means±standard
deviation (n=3).
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Fig. 2 Free FA originating from formulation digestion as a function of
time. Values (means±standard deviation, n=3) were corrected for
background lipolysis (pure lipolysis medium) and include additional FA
detected by back-titration.
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Raman Spectroscopy
The Raman spectra of fenofibrate in the crystalline and
solubilized forms displayed a characteristic pattern, as seen
in Fig. 5a. Unprocessed spectra are depicted, which were
recorded during the lipolysis experiment at different time
points (drug load: 70 mg/g). Moreover, the Raman spectra
of crystalline fenofibrate and of the drug-free lipolysis me-
dium are shown. The spectra recorded after 40 s, 5 min, and
30 min of lipolysis displayed noticeable variations in the
range of 1132 – 1164 cm−1 and 1550 – 1663 cm−1.
A PLS model was built for the concentration of crystallized
fenofibrate based on a set of 42 spectra, as detailed in Table I.
The reference values were mostly selected from concentrations
and time points that demonstrated consistent results in both
off-line methods (i.e., ultracentrifugation and nanofiltration).
The concentrations in samples with a drug load of 50 –
80 mg/g, assayed at 25 and 30 min of digestion, were consis-
tent between the two methods and were therefore used for
model calibration of the corresponding spectra. To further
include spectra of digests without precipitate, we relied on
the data from the nanofiltration method. According to these
results, the concentration of solubilized drug after 1 min of
lipolysis was not significantly different from the concentration
before initiation of lipolysis (p>0.05 in all cases). This observa-
tion indicates that no precipitation occurred during the first
minute of digestion. Therefore, for model calibration we se-
lected the earliest spectrum (i.e., the spectrum that was ac-
quired 40 s after lipolysis initiation) of each formulation with
a drug load of 20 – 70 mg/g and set Cpr equal to zero. The
80 mg/g drug load was excluded from this part of the
calibration.
We evaluated different methods for data preprocessing.
Two scatter-correction methods (MSC, SNV) and a deriv-
ative method (SG) were compared (38–40). Moreover, three
different spectral ranges were considered for model
calibration. Table II compares the performance of calibra-
tion models that were obtained using the different pre-
processing methods and spectral ranges. The best
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Fig. 5 Part (a) depicts the unprocessed Raman spectra of drug-free lipolysis
medium (I), lipolysis medium with fenofibrate after 40s (II), 5 min (III), and
30 min (IV) digestion periods, and pure fenofibrate (V). Plots of the weights of
the first PLS factor (b) and scores over time of all three PLS factors used in the
PLS model (c). The numbers in (c) represent the variance captured in the
corresponding PLS factor. All plots are offset for clarity.
Table I Calibration Set as Used for Quantitative Application of Raman
Spectroscopy
Cform (mg/g) Time span of
acquisition (s)
Cpr (mg/ml) Total number of
calibration spectra
20, 30, 40, 50, 60, 70 20–40 0 18
50, 60, 70, 80 1480–1500 Cpr
a 12
50, 60, 70, 80 1780–1800 Cpr
a 12
a Results obtained using the ultracentrifugation method
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Fig. 4 XRPD pattern of the pellet phase obtained upon ultracentrifugation
and resulting from (a) the formulation with 80 mg/g fenofibrate, (b) the
pellet phase of drug-free formulation spiked with crystalline fenofibrate, and
(c) pure crystalline fenofibrate.
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calibration model was attained with the SG algorithm (1st
derivative) and a spectral range between 1000 and
1800 cm−1. Three PLS factors described 99.4% of the
spectral variation, with an R2 value of 0.994, while the first,
second, and third factors accounted for 96.6%, 1.4%, and
1.3% of the variation, respectively. Only the first PLS factor
is shown in Fig. 5b, as it accounted for most of the variation.
Herein, three ranges with a high PLS weight were identi-
fied, which corresponded to the peaks of the crystalline
fenofibrate. The second and the third factors contributed
to the model variation to a lower extent. However, they
may account for residual non-linearity in the data set as seen
in Fig. 5c. The cross-validation procedure yielded a Q2
value of 0.972 and an RMSECV of 0.111 mg/ml, indicating
a robust calibration model.
Finally, we applied this calibration model to all other
Raman spectra to determine the precipitation profiles over
a 30 min digestion period. Figure 3c shows that fenofibrate
precipitated after an initial lag time in all formulations with
drug loads of more than 30 mg/g. Minimal drug precipita-
tion was observed for the formulation with a drug load of
20 mg/g.
In summary, the comparison of fenofibrate precipitation
profiles (Fig. 3a, b, and c) demonstrated an excellent agree-
ment between the nanofiltration and the spectroscopic meth-
ods. Both methods suggested that drug precipitated only after
an initial lag phase. This was in contrast to the ultracentrifu-
gation method, which indicated precipitation almost immedi-
ately after digestion started.
Modeling the Kinetics of Lipolysis-Triggered Drug
Precipitation
The high temporal resolution of in-line Raman spectroscopy
encouraged a more detailed analysis of drug precipitation
kinetics. The theories of nucleation and growth (Eqs. 2 and 4)
were applied to model the course of lipolysis-triggered drug
precipitation. Before lipolysis initiation, drug concentration in
the lipolysis mediumwas below saturation. Enzymatic digestion
of lipids resulted in a diminished drug solubilization, which in
turn induced supersaturation and led to drug precipitation.
Because the drug solubility changed continuously through
ongoing lipolysis, an expression for time-dependent solubility
was introduced.
The progress of lipolysis is reflected by the amount of FA
titrated as a function of time (Fig. 2). These data show that
lipolysis occurred rapidly at first and then slowed down con-
siderably. By drawing two straight lines through the data
points between 0 and 40 s, and between 16.6 and 30 min,
we found the intersection point, tx, at 82.1 s. This time point
was used to define the transition of the initial rapid lipolysis
stage to the second, slow, lipolysis stage. Based on the titration
data and the stoichiometry of hydrolysis, we calculated the
amount of glycerides that were apparently hydrolyzed in these
two stages (Fig. 6a), and compared it with the amount of
formulation lipids. The good agreement between experimen-
tal data (Fig. 6a), and the formulation composition (Table III)
supports the view that the first stage corresponded primarily to
the hydrolysis of TG and DG, whereas the second stage was
attributable to the hydrolysis ofMG. The latter value included
MG, those present in the formulation (Imwitor® 988) and
those generated from the lipolysis of sn-1,3 DG. In contrast,
sn-2MG resulting from the digestion of TGwere assumed not
to be further hydrolyzed (46). With respect to the different
enzyme activities, we expected rapid digestion of DG and TG
by the pancreatic lipase and co-lipase, whereas the activity of
the carboxyl ester hydrolase is known to be comparatively low
(34,35). This difference in lipolysis rates was in good agree-
ment with our observations, as DG and TG were digested
considerably faster than MG. The amount of digested
Table II PLS Analysis Results
of Raman Spectroscopy
aParameters used in the Savitzky-
Golay algorithm: window size 10
points, 1st derivative, 2nd
polynomial.
bSpectral ranges:
A=500–1800 cm−1;
B=1000–1800 cm−1;
C=1132–1164, 1550–1615,
1635–1663 cm−1
Pre-processing method Spectral
rangeb
PLS factors R2 Q2 RMSEC
(mg/ml)
RMSECV
(mg/ml)
None A 5 0.985 0.969 0.0142 0.113
B 4 0.985 0.959 0.0104 0.129
C 3 0.979 0.960 0.0501 0.112
SNV A 3 0.984 0.907 0.0298 0.194
B 3 0.988 0.962 0.0199 0.152
C 4 0.953 0.962 0.0108 0.124
MSC A 4 0.985 0.958 0.0129 0.132
B 3 0.978 0.958 0.0133 0.132
C 3 0.982 0.966 0.0158 0.117
SGa A 3 0.993 0.971 0.0083 0.117
B 3 0.994 0.972 0.0079 0.111
C 3 0.990 0.969 0.0099 0.111
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TG and DG (M1(t)) and of digested MG (M2(t)) was found
to be well described by a logarithmic function of time (R2>
0.99), as shown by the fitted lines in Fig. 6a.
These findings of lipolysis kinetics were used to propose a
mathematical expression for solubility as a function of time.
It was assumed that two phases contributed to overall solu-
bility. An oil phase consisted of TG and DG, whereas a
colloidal phase consisted primarily of MG. Both contribu-
tions to the total solubility were considered additively.
Therefore, drug solubility in the first and second stages of
lipolysis was given by Eqs. 5 and 6, respectively. Figure 6b
demonstrates that the curve, which was calculated (not
fitted) using these equations, accurately reflected the exper-
imental solubility values. The drug solubility at 82.1 s was
found by interpolation and corresponded to a value of
0.39 mg/ml. It must be mentioned that no single mathe-
matical expression was able to describe adequately the
change in drug solubility over the entire time course of
lipolysis.
Equations 2 and 4 were combined with Eqs. 5 and 6
to give the system of differential equations (Eqs. 7–11),
which was fitted to the concentration data obtained by
Raman spectroscopy. The model was found to excel-
lently describe the experimental concentrations of pre-
cipitated drug (R2>0.975) at all drug loads (Fig. 7).
Table IV details the values of A, B, kg, g, tn, and tg
that were estimated from this optimization. The nucle-
ation parameters A and B had comparable values for
all studied drug loads, while the nucleation induction
time, tn, increased with decreasing drug load. The
growth parameters exhibited values within a similar
range for each drug load. No fitting was carried out for the
smallest drug loads of 20 and 30 mg/g because of the large
scatter in Raman data.
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Fig. 6 TG and DG digestion (white square) and sn-1 MG digestion (white
circle) over time, as calculated based on titrated FA and the stoichiometry of
glyceride hydrolysis according to the literature (a). The solid lines represent
the logarithmic functions of time fitted to these time courses (M1(t)=
0.57∙ln(t)+2.37 and M2(t)=1.12∙ln(t) - 0.419, respectively). (b) Fenofi-
brate solubility in the lipolysis medium as determined experimentally at
different lipolysis times (circles) and as calculated from Eqs. 5 and 6 (solid
line).
Table III Estimation of the Amount of FA Liberated from 2.6 g SMEDDS According to Assumptions Inferred from the Literature (34,35,46) and Maximal
Amount of Hydrolysable Ester Bonds in 2.6 g SMEDDS
Excipient Composition in SMEDDS
(% w/w)
Excipient composition
(% w/w)
Excipient in 2.6 g
formulation (mmol) b
FA liberation according
to the literaturea (mmol)
Max. available FA
(mmol)
Miglyol 812 40 100 (TG) 2.01 4.03† 6.04
Imwitor® 988 20 54.6 (MG) 1.45 1.45‡ 1.45
38.0 (DG) 0.58 0.58† and 0.58‡ 1.16
7.1 (TG) 0.077 0.15† 0.23
Cremophor® RH 40 40 100 (TG) 0.39 0.09‡ 1.16
a TG in Miglyol 812 and Imwitor® 988 are digested to sn-2 MG and 2 FA; sn-1,3 DG in Imwitor® 988 are digested to sn-1 MG and 1 FA , and then to
glycerol and 1 FA; sn-1 MG in Imwitor® 988 are digested to glycerol and FA; Cremophor® RH 40 was assumed to be hydrolyzed by 7.5% (w/w) according
to Cuiné et al. (5). Digestion of TG to sn-1,2 DG and sn-2 MG and of sn-1,3 DG to sn-1 MG was assumed to occur rapidly († , first stage), while the
digestion of Cremophor® RH 40 and of sn-1 MG to glycerol and FA was supposed to occur slowly (‡ , second stage)
b Average molecular weights (g/mol) used for calculation: 516.8 (Miglyol 812), 196.2 (MG in Imwitor 988), 339.4 (DG in Imwitor® 988), 482.6
(TG in Imwitor® 988), 2699 (Cremophor® RH 40 (5))
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DISCUSSION
Detection of Drug Precipitation During In Vitro
Lipolysis
The fate of a LBDDS in the gastrointestinal tract is decisive
for drug absorption and, therefore, for the performance of
the formulation. Poorly water-soluble drugs often precipi-
tate from lipid-based systems already upon dispersion in
aqueous fluids. Such potentially inferior systems can be
identified early in formulation screening using simple in vitro
dilution and dispersion tests (47). Other formulations exhibit
drug precipitation in the course of formulation digestion.
The analysis of such lipolysis-triggered drug precipitation
was the main focus of the present work.
Traditionally, drug solubilization during in vitro lipol-
ysis is analyzed using methods that rely on a sampling
regime. Accordingly, aliquots of the digest are drawn
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precipitated fenofibrate as
measured with Raman
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Table IV Results of Parameter
Estimation of Drug Precipitation
Kinetics
Cform (mg/g) A (10
−3mg∙ml-3s−1) B tn (s) tg (s) kg (10
−3s−1) g R2 RMSE (mg/ml)
80 2.0 6.1 149.0 291.0 9.0 0.8 0.990 0.052
70 2.9 4.8 210.5 395.2 7.3 0.9 0.987 0.052
60 2.0 6.6 300.2 478.7 9.0 1.4 0.992 0.041
50 2.8 6.3 335.9 671.7 8.4 1.2 0.978 0.051
40 1.6 6.2 362.0 824.8 8.2 1.3 0.976 0.040
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from the lipolysis medium at defined time points and
the concentration of solubilized and/or precipitated
drug is usually measured following ultracentrifugation.
This approach has so far provided fundamental knowl-
edge on the lipolysis of lipid-based systems as well as
the in vitro fate of poorly water-soluble drugs. However,
real-time monitoring seems to be essential to further
analyze the dynamic changes of the formulation and
to study effects of drug supersaturation.
The first aim of this study was to evaluate Raman spec-
troscopy for real-time monitoring of drug precipitation dur-
ing in vitro lipolysis. A model SMEDDS containing
fenofibrate was digested using a common lipolysis test (7).
The application of Raman spectroscopy to in vitro lipolysis
represented a particularly challenging case for monitoring of
crystallization. While classical crystallization monitoring in
chemical processes usually involves high drug concentra-
tions and a constant medium, the present application of
Raman spectroscopy had to cope with low analyte concen-
trations in a changing digestion medium. The hydrolysis
products interfered with the drug-related Raman signal
and had to be considered in the interpretation of spectra.
Moreover, the two off-line methods (ultracentrifugation and
nanofiltration) revealed some conflicting results, which led
to an even more challenging development of a robust cali-
bration model. Hence, an accurate selection of instrumental
parameters, chemometric procedures, and reference meas-
urements was required.
The time courses of drug precipitation obtained from the
two off-line sample preparation methods were dissimilar,
particularly in the initial stage of precipitation. This differ-
ence was likely due to additional drug precipitation occur-
ring during sample ultracentrifugation. Even though
ultracentrifugation was proven to separate the solid, aque-
ous, and oil phases efficiently (11), the influence of sample
preparation on drug precipitation can barely be avoided.
First, there was an unavoidable time delay of up to 30 min
between sample removal and ultracentrifugation. Second,
we allowed ultracentrifugation to proceed for 90 min. This
step usually takes a shorter time (30 min (11)), but we
deliberately selected an extreme condition (90 min (48)) to
simulate a worst-case sample preparation. These steps in-
troduced time delays during which the drug could further
precipitate. Therefore, the results of the ultracentrifugation
method might not provide the actual kinetic concentration
but rather an advanced stage of drug precipitation. This
assumption was supported by the observation that drug
concentrations in the aqueous phase, as measured upon
ultracentrifugation, were almost equal to the corresponding
solubilities. In contrast, the nanofiltration method allowed a
more rapid separation of the liquid phase. This method has
proven to effectively separate undissolved drug from colloi-
dal drug solutions in biorelevant release tests (37).
The selection of calibration spectra and reference meas-
urements relied on these previous findings. According to the
nanofiltration results, the concentration of solubilized drug
did not significantly change within the first minute of lipol-
ysis. This observation proved that fenofibrate did not pre-
cipitate instantaneously when lipolysis was started, but only
after an initial lag phase. It was therefore justified to include
the earliest spectra and the corresponding nanofiltration
result within the calibration set. Between 25 and 30 min of
digestion, the nanofiltration and ultracentrifugation meth-
ods yielded consistent results and thus the corresponding
spectra and reference values were included in the calibra-
tion set. Finally, between 40 s and 25 min there was a lack of
reliable reference measurements, hence those spectra were
excluded from the set of calibration spectra.
The generation of lipolysis products led to a notable
increase in medium turbidity. This light scattering origi-
nated mostly from FA precipitation in the presence of
calcium and from precipitated drug. To reduce particle-
size effects, we selected adequate sampling optics consist-
ing of a large spot-size Raman probe (49). Furthermore,
we evaluated different pre-processing algorithms for the
entire set of Raman spectra prior to PLS regression
analysis. This was necessary to correct for light scattering
and residual particle-size effects (40). We found that an SG
smoothing and differentiation filter (1st derivative) was best for
reducing this systematic variation. Residual sources of non-
linearity were finally corrected by a three-component PLS
regression model, while cross-validation demonstrated good
robustness.
After spectra pre-processing and calibration, we applied
the resultant quantification model to the entire data set. The
real-time data demonstrated that drug started to precipitate
after a lag phase of 3 to 6min, while this period decreased with
increasing drug load. Interestingly, there was excellent agree-
ment between the course of drug precipitation obtained from
Raman spectroscopy and from the nanofiltration method,
even though only spectra from the initial and final time points
were included in the calibration set.
Raman spectroscopy demonstrated clear advantages
compared with the traditional ultracentrifugation method.
The main issue in the latter method was the time delay
caused by sample preparation. The application of benchtop
centrifugation instead of ultracentrifugation, as proposed in
a recent publication (11), could reduce this time delay.
However, temporal resolution is still better using an in situ
method such as Raman spectroscopy.
In contrast to ultracentrifugation, conventional Raman
spectroscopy may be barely able to determine drug solubili-
zation in the aqueous and the oil phases separately. However,
the authors of a recent study suggested that the concentration
of solubilized drug in the entire medium (and not only in the
aqueous phase) may be the relevant measure for predicting
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intestinal permeation of a drug (14). In this respect Raman
spectroscopy can provide the relevant data for estimating the
absorbable dose fraction. Even though Raman spectroscopy
was applied to the quantification of crystalline drug in the
present case, the technique would also be able to quantify
amorphous drug precipitation. This is certainly an advantage
over, for example, in situXRPD.However, the combination of
XRPD and Raman spectroscopy is certainly of interest for
studying transient polymorphic changes (50).
Kinetics of Lipolysis-Triggered Drug Precipitation
The second aim of the study was to determine the kinetics of
drug precipitation during formulation lipolysis. Modeling
precipitation kinetics may offer advantages in the biophar-
maceutical characterization of lipid-based systems. Indeed,
the amount of drug available for absorption does not only
depend on whether or not the drug precipitates in the
gastrointestinal lumen. Besides improving drug solubility,
lipid-based formulations can increase bioavailability by the
temporary stabilization of a drug in the supersaturated state.
Although it is in a metastable condition, this induction time
is particularly relevant for compounds with good permeabil-
ity. Indeed, supersaturation generates an increased flux
across the intestinal membrane and precipitation in vivo
may be reduced or even be absent. This awareness is crucial
for formulation development. Drug supersaturation and the
solid-state properties of a precipitate are often neglected
during industrial screening tests of lipid-based formulations.
Such candidate systems generally drop out of screening
programs and, consequently, there is a risk of excluding
candidate formulations that may still exhibit sufficient oral
availability in vivo. Physiologically based pharmacokinetic
(PBPK) models are valuable tools for predicting the formu-
lation behavior in vivo on the basis of characteristics that are
measured in vitro (47). These models consider drug release
and absorption as a dynamic interplay to predict the bioavail-
ability of a drug. However, to obtain a precise estimation,
PBPK modeling requires accurate prediction of supersatura-
tion and potential drug precipitation during formulation dis-
persion and/or lipolysis.
Nucleation and Growth Model
We presented a nucleation and growth model that consid-
ered the dynamic changes in drug solubility during formu-
lation digestion. The new model successfully described the
data of lipolysis-triggered fenofibrate precipitation and
yielded reasonable parameter values. The kinetic and ther-
modynamic pre-factors of the nucleation rate, A and B,
respectively, were consistent for different drug loads and
are in good agreement with the literature (44). For such
comparison, it has to be noted that the pre-factor A is here
expressed as a mass concentration per unit time. The
growth constant kg and the exponent g were also in accor-
dance with previously reported values (45).
When comparing the kinetics of drug precipitation with the
kinetics of formulation lipolysis, we observed a non-linear
correlation between the two variables (Fig. 8). This was inter-
esting in relation to the findings of Sassene et al., who observed
linearity between precipitated cinnarizine and titrated FA
using a self-microemulsifying formulation (24). In this previous
study, continuous calcium addition and the different sample
preparationmethod (ultracentrifugation) may have influenced
the observed kinetics. To clarify such effects, more studies that
compare the different lipolysis tests using the same drug for-
mulation are certainly needed.
Our study indicates that the nucleation time tn decreased
with increasing drug load, i.e., with higher levels of super-
saturation, in good agreement with expectation, as the de-
gree of supersaturation generally decreases the induction
period (45). This dependence is highly relevant for selecting
the adequate dose strength. Accordingly, the administration
of a single lipid-based capsule with high dose strength might
result in a different pharmacokinetic profile compared with
the administration of multiple units at lower dose strength.
These considerations are in good agreement with a recent
attempt to study the effects of drug loading on the lipolysis of
lipid-based formulations (51).
Several studies used the in vitro digestion model to predict
formulation performance in vivo. However, limited correlation
between in vitro solubilization and in vivo exposure was often
apparent. For instance, in an attempt to prove supersaturation
stabilization in SEDDS with polymers, Anby et al. showed a
clearly beneficial effect of polymer addition upon in vitro
digestion, but no correlation was found with in vivo data (4).
Other studies showed an agreement between in vitro and in vivo
data, but primarily as a rank-order correlation (48,52–55). An
improved characterization of drug supersaturation, precipita-
tion, and re-dissolution might be the key to better understand
the pharmacokinetic processes in vivo. To this end, real-time
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Fig. 8 Fenofibrate precipitation as a function of titrated FA. Each color
represents a single drug loading and is the mean value of three
experiments.
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Raman spectroscopy, together with mathematical modeling
of lipolysis-triggered drug precipitation, could play an impor-
tant role. These techniques may become part of future drug
absorption modeling and improve the predictivity of in vitro-in
vivo correlations.
Drug Solubility as a Function of Time
An important part of the presented nucleation and growth
model was to consider the change in drug solubility as a
function of time. The proposed heuristic function was in line
with previous studies that proved a direct correlation between
drug solubility and the concentration of formulation compo-
nents and digestion products (18,56,57). However, some dis-
cussion is needed to explain why the present heuristic approach
was proposed.
The pancreatin extract consisted of a mixture of digestive
enzymes and co-enzymes, most importantly pancreatic li-
pase and co-lipase, as well as carboxyl ester hydrolase
(58,59). These enzymes exhibit different lipolytic activities
and substrate specificities, as described previously
(34,35,46,60). These properties of lipolytic enzymes and
the composition of the model formulation suggested that
lipolysis occurred in two stages. Pancreatic lipase and co-
lipase are known to rapidly hydrolyze TG and DG at the sn-
1,3 position, yielding sn-2 MG and FA as digestion prod-
ucts. It is assumed that this substrate specificity is due to the
high affinity of the pancreatic lipase and co-lipase to insoluble
lipids (34,35). In contrast, the second stage was likely charac-
terized by the digestion of MG, which is catalyzed mostly by
carboxyl ester hydrolase. This enzyme has high affinity to
lamellar structures and micelles containingMG and its lipolytic
activity is lower than that of pancreatic lipase (34,35). Although
the regioselectivity of carboxyl ester hydrolase is still a debated
topic, it is assumed to cleave MG preferentially at the sn-1
position (60,61). Sek et al. quantified the digestion products of
medium-chain and long-chain glycerides upon in vitro digestion,
using the same experimental conditions as in the present study
(46). Interestingly, sn-2 MG were weakly digested by porcine
digestive enzymes, whereas sn-1 MG were hydrolyzed to a
large extent. For this reason, we assumed that primarily sn-1
MG were digested in the second stage of lipolysis.
The amounts of DG and TG hydrolyzed during the first
stage of lipolysis (as obtained from the titration data) were in
good agreement with the nominal amount of lipids that was
present in the formulation. For the second stage of lipolysis, we
expected sn-1 MG and a small fraction of Cremophor® RH
40 to be hydrolyzed (Table III, FA liberation according to the
literature). Interestingly, considering these assumptions, the
amount of titrated FA exceeded the expected FA liberation.
This observation could originate from higher Cremophor®
RH 40 hydrolysis than the reported fraction of 7.5% (5). This
value was obtained from the in vitro lipolysis of pure excipient
and it might not be the same for Cremophor® RH 40 diges-
tion in a lipid mixture. Care is needed when assuming that a
single excipient is digested equally to when it is present in
combination with an oil phase in a formulation. The situation
is particularly complex for surfactants, as they are known to
act as substrates and as inhibitors of lipolytic enzymes (5). A
further explanation for the observed lipolysis degree is that
some sn-2 MG were further digested. Mattson and
Volpenhein observed that a small fraction of sn-2 MG
exhibited a non-enzymatic isomerization to sn-1 MG
(62). In line with their observation, it seems possible that a
small amount of sn-2 MG exhibited isomerization and was
further digested.
As a result, the proposed equation for fenofibrate solubility
as a function of time was in very good agreement with the
experimental solubility values. DG and TG were the most
lipophilic glycerides present in the formulation. Therefore, the
removal of these compounds was correlated with a pro-
nounced decrease in fenofibrate solubilization. In contrast,
we measured a less pronounced decrease during the second
stage of lipolysis because of the smaller contribution of MG to
solubilization.
CONCLUSIONS
Real-time analytics is fundamental to gain an improved un-
derstanding of the highly dynamic processes of formulation
digestion. In this study we evaluated the quantitative applica-
tion of Raman spectroscopy for real-time monitoring of drug
precipitation during in vitro lipolysis. The method was com-
pared with two off-line procedures, which were based on a
sampling regime. Raman spectroscopy measured fenofibrate
precipitation with a high temporal resolution and minimal
experimental bias. In contrast, care is needed when determin-
ing the kinetics of drug precipitation by methods that require
sample preparation. Indeed, the lag time between sample
removal and analysis could lead to further drug precipitation.
The precipitation profiles obtained by Raman spectroscopy
were used to model the kinetics of lipolysis-triggered drug
precipitation. We introduced a mathematical model, which
was based on theoretical equations of nucleation and growth
by considering solubility changes over time. This model pro-
vided an excellent prediction of fenofibrate crystallization dur-
ing lipolysis. The drug began to precipitate after an initial lag
phase of supersaturation. The temporary supersaturation is not
only of theoretical interest. This metastable state is particularly
important for poorly water-soluble compounds with high per-
meability, i.e., when the process of drug precipitation occurs in
a similar time span as drug absorption.
The proposedmodel for lipolysis-triggered drug precipitation
may be part of more complex pharmacokinetic models.
Physiologically based drug absorption models are particularly
3128 Stillhart, Imanidis and Kuentz
interesting in this aspect. More refined mechanistic modeling
of this type will ultimately help to better predict the fate of a
LBDDS in vivo.
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